Search
RLYB212
go.drugbank.com/drugs/DB17727InvestigationalRLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.
SAR-439459
go.drugbank.com/drugs/DB17864InvestigationalSAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody.[A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
AB-201
go.drugbank.com/drugs/DB18629InvestigationalAB-201 is a CAR-NK cell therapy targeted against HER2.[L48340] It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.
AEF0117
go.drugbank.com/drugs/DB27675InvestigationalAEF0117 is a small molecule drug. AEF0117 is under investigation in clinical trial NCT05554926 (Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects).
Trametes versicolor fruiting body
go.drugbank.com/drugs/DB14287InvestigationalTrametes versicolor fruiting body is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Styphnolobium japonicum flower bud
go.drugbank.com/drugs/DB14294InvestigationalStyphnolobium japonicum flower bud is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Camellia japonica seed oil
go.drugbank.com/drugs/DB14308InvestigationalCamellia japonica seed oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Chamaecyparis obtusa wood oil
go.drugbank.com/drugs/DB14341InvestigationalChamaecyparis obtusa wood oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Products: Phytoncide SuRosa centifolia flower oil
go.drugbank.com/drugs/DB14363InvestigationalRosa centifolia flower oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
MBP134
go.drugbank.com/drugs/DB18686ExperimentalMBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).